• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比较换用 BIC/TAF/FTC 与初始使用 BIC/TAF/FTC 的情况下，对接受抗病毒治疗病毒学抑制的 HIV 感染者进行回顾性观察。

A retrospective observation of virologically suppressed people living with HIV by comparing switching to BIC/TAF/FTC with initial use BIC/TAF/FTC.

机构信息

Department of Pharmacy, The People's Hospital of Yubei District of Chongqing City, Chongqing, China.

Department of Infectious Diseases, The People's Hospital of Yubei District of Chongqing City, Chongqing, China.

出版信息

Ann Med. 2023;55(2):2305692. doi: 10.1080/07853890.2024.2305692. Epub 2024 Jan 18.

DOI:10.1080/07853890.2024.2305692
PMID:38237196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10798279/
Abstract

BACKGROUND

The objective of this study was to observe retrospectively the clinical response of virologically suppressed people living with HIV (PLWH) by comparing switching to BIC/TAF/FTC with initial use BIC/TAF/FTC.

METHODS

PLWH using BIC/TAF/FTC was divided into 'initial use' group and 'switching to' group. Immune response, metabolic parameters and renal function between the two groups were analysed.

RESULTS

The CD4 cell counts was higher in post- treatment than pre- treatment in the 'switching to' group (416.54 ± 212.11 cells/mm vs. 243.72 ± 156.64 cells/mm,  < .001); however, significant differences were not observed in the 'initial use' group ( = .658). The effect of BIC/TAF/FTC on metabolism was not obvious. Serum creatinine (SCr) was improved in post-treatment than in pre-treatment in 'switching to' group (69.03 ± 18.78 vs. 77.52 ± 20.18,  < .001). Platelet count was lower in post-treatment than pre-treatment both in the 'initial use' group (175.81 ± 69.27 vs. 202.90 ± 66.56,  = .070) and in the 'switching to' group (177.04 ± 64.48 vs. 212.53 ± 63.43,  < .001).

CONCLUSIONS

'Switching to' is superior to 'initial use' BIC/TAF/FTC in immune response among PLWH. The effect of BIC/TAF/FTC on metabolism is not obvious. BIC/TAF/FTC related thrombocytopenia needs to be further explored.

摘要

背景

本研究旨在通过比较转换为 BIC/TAF/FTC 与初始使用 BIC/TAF/FTC，观察对病毒抑制的 HIV 感染者（PLWH）的临床反应。

方法

将使用 BIC/TAF/FTC 的 PLWH 分为“初始使用”组和“转换”组。分析两组间免疫反应、代谢参数和肾功能。

结果

“转换”组治疗后 CD4 细胞计数高于治疗前（416.54±212.11 个/毫米 vs. 243.72±156.64 个/毫米，  < .001）；而“初始使用”组则无明显差异（  = .658）。BIC/TAF/FTC 对代谢的影响不明显。“转换”组治疗后血清肌酐（SCr）优于治疗前（69.03±18.78 与 77.52±20.18，  < .001）。两组治疗后血小板计数均低于治疗前（“初始使用”组：175.81±69.27 与 202.90±66.56，  = .070；“转换”组：177.04±64.48 与 212.53±63.43，  < .001）。

结论

PLWH 中“转换”优于“初始使用”BIC/TAF/FTC 的免疫反应。BIC/TAF/FTC 对代谢的影响不明显。BIC/TAF/FTC 相关的血小板减少症需要进一步探讨。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/10798279/8cc4b545f81a/IANN_A_2305692_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/10798279/8cc4b545f81a/IANN_A_2305692_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/10798279/8cc4b545f81a/IANN_A_2305692_F0001_B.jpg

相似文献

1
A retrospective observation of virologically suppressed people living with HIV by comparing switching to BIC/TAF/FTC with initial use BIC/TAF/FTC.比较换用 BIC/TAF/FTC 与初始使用 BIC/TAF/FTC 的情况下，对接受抗病毒治疗病毒学抑制的 HIV 感染者进行回顾性观察。
Ann Med. 2023;55(2):2305692. doi: 10.1080/07853890.2024.2305692. Epub 2024 Jan 18.
2
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.在美国，接受单片制剂达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺治疗的 HIV-1 感染者中体重指数增加和体重增加的情况。
Curr Med Res Opin. 2022 Feb;38(2):287-298. doi: 10.1080/03007995.2021.2007006. Epub 2021 Dec 7.
3
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.切换至比克替拉韦/恩曲他滨/丙酚替诺福韦艾拉酚胺治疗，可维持既往存在抗反转录病毒耐药（包括 M184V/I）的患者 HIV-1 RNA 抑制。
J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347.
4
Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69).从 EVG/Cobi/FTC/TAF 换用 BIC/FTC/TAF（PreEC/RIS69）的患者的短期神经精神和体重变化。
Curr HIV Res. 2022;20(3):251-254. doi: 10.2174/1570162X20666220608160335.
5
Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.在经病毒学控制的 HIV 感染者中，从比克替拉韦/恩曲他滨/丙酚替诺福韦二吡呋酯转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺富马酸盐后免疫重建和安全代谢特征：来自 BICTEL 队列的 96 周更新。
Viruses. 2023 May 23;15(6):1222. doi: 10.3390/v15061222.
6
Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.多中心队列研究中的比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺：来自西班牙的真实生活经验
Ann Pharmacother. 2024 Feb;58(2):140-147. doi: 10.1177/10600280231168852. Epub 2023 May 2.
7
Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study.蛋白酶抑制剂或非核苷类逆转录酶抑制剂病毒学失败患者换用比克替拉韦/恩曲他滨/丙酚替诺福韦后的结局：一项真实世界队列研究。
Infect Drug Resist. 2021 Nov 23;14:4877-4886. doi: 10.2147/IDR.S331647. eCollection 2021.
8
Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis.一组HIV感染者改用比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨的病毒免疫、临床结局及成本：一项48周的前瞻性分析
Biomedicines. 2022 Jul 28;10(8):1823. doi: 10.3390/biomedicines10081823.
9
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.简报：在有治疗经验的 HIV 感染者中，比克替拉韦和替诺福韦与达芦那韦/考比司他联合应用的药代动力学。
J Acquir Immune Defic Syndr. 2021 Dec 1;88(4):389-392. doi: 10.1097/QAI.0000000000002765.
10
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.恩曲他滨/丙酚替诺福韦（FTC/TAF）与恩曲他滨/富马酸替诺福韦二吡呋酯（FTC/TDF）作为病毒学抑制的成年HIV-1感染者治疗基础用药的疗效和安全性：一项随机、双盲、活性对照3期试验的第三药物亚组分析
HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17.

本文引用的文献

1
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为初治HIV-1的治疗：两项随机试验的五年随访
EClinicalMedicine. 2023 May 11;59:101991. doi: 10.1016/j.eclinm.2023.101991. eCollection 2023 May.
2
Immune response to ART initiation in advanced HIV infection.晚期 HIV 感染患者接受抗逆转录病毒治疗（ART）时的免疫反应。
HIV Med. 2023 Jun;24(6):716-726. doi: 10.1111/hiv.13467. Epub 2023 Feb 15.
3
Human Immunodeficiency Virus: Opportunistic Infections and Beyond.
人类免疫缺陷病毒：机会性感染及其他问题。
Neuroimaging Clin N Am. 2023 Feb;33(1):147-165. doi: 10.1016/j.nic.2022.07.014.
4
Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis.一组HIV感染者改用比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨的病毒免疫、临床结局及成本：一项48周的前瞻性分析
Biomedicines. 2022 Jul 28;10(8):1823. doi: 10.3390/biomedicines10081823.
5
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.欧洲艾滋病临床学会指南 2021 年第 11.0 次重大修订版。
HIV Med. 2022 Sep;23(8):849-858. doi: 10.1111/hiv.13268. Epub 2022 Mar 25.
6
Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.初治个体的晚期HIV感染：推荐的三联药物治疗方案的有效性和持久性
Open Forum Infect Dis. 2022 Jan 13;9(3):ofac018. doi: 10.1093/ofid/ofac018. eCollection 2022 Mar.
7
Treatment initiation or switch to BIC/FTC/TAF - real-world safety and efficacy data from two HIV centers in Romania.开始治疗或换用比克替拉韦/恩曲他滨/丙酚替诺福韦——来自罗马尼亚两个艾滋病治疗中心的真实世界安全性和有效性数据。
Germs. 2021 Dec 29;11(4):512-522. doi: 10.18683/germs.2021.1286. eCollection 2021 Dec.
8
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.在一个大型参考临床中心使用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺的真实临床经验。
J Antimicrob Chemother. 2022 Mar 31;77(4):1133-1139. doi: 10.1093/jac/dkab481.
9
Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study.蛋白酶抑制剂或非核苷类逆转录酶抑制剂病毒学失败患者换用比克替拉韦/恩曲他滨/丙酚替诺福韦后的结局：一项真实世界队列研究。
Infect Drug Resist. 2021 Nov 23;14:4877-4886. doi: 10.2147/IDR.S331647. eCollection 2021.
10
Hematologic cancers in individuals infected by HIV.感染HIV的个体中的血液系统癌症。
Blood. 2022 Feb 17;139(7):995-1012. doi: 10.1182/blood.2020005469.